Felix P Mayer, Adele Stewart, Durairaj Ragu Varman, Amy E Moritz, James D Foster, Anthony W Owens, Lorena B Areal, Raajaram Gowrishankar, Michelle Velez, Kyria Wickham, Hannah Phelps, Rania Katamish, Maximilian Rabil, Lankupalle D Jayanthi, Roxanne A Vaughan, Lynette C Daws, Randy D Blakely, Sammanda Ramamoorthy
Aberrant dopamine (DA) signaling is implicated in schizophrenia, bipolar disorder (BPD), autism spectrum disorder (ASD), substance use disorder, and attention-deficit/hyperactivity disorder (ADHD). Treatment of these disorders remains inadequate. We established that the human DA transporter (DAT) coding variant (DAT Val559), identified in individuals with ADHD, ASD, or BPD, exhibits anomalous DA efflux (ADE) that is blocked by therapeutic amphetamines and methylphenidate. As the latter agents have high abuse liability, we exploited DAT Val559 knock-in mice to identify non-addictive agents that can normalize DAT Val559 functional and behavioral effects ex viv o and in vivo ...
May 3, 2023: bioRxiv